Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

NSCLC Clinical Trial

Official title:

Efficacy and Safety of Toripalimab Adjuvant Therapy in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) After Complete Resection: a Prospective, Single-arm Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06221670
• Other study ID #: NSCLC-Toripalimab-001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 20, 2024
• Est. completion date: March 20, 2031

Study information

• Verified date: January 2024
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Dongsheng Yue
• Phone: +8602223109106
• Email: yuedongsheng_cg[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central laboratory. To evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 51
• Est. completion date: March 20, 2031
• Est. primary completion date: March 20, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subjects will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;

• Male and female, =18 years old;

• Primary non-squamous NSCLC confirmed histologically by the central laboratory;

• The subject was clinically confirmed as stage IA2-IB by imaging with tumor lesion size > 2 cm;

• As confirmed by the central laboratory, the tumor contains no common EGFR mutations and ALK fusion variants;

• The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS);

• Central laboratory pathology confirmed solid and/or micropapillary component =10%, and/or STAS, and/or pleural invasion, and/or poorly differentiated, and/or complex glands = 10%; PD-L1 TPS = 1% in tumor tissue;

• WHO physical status score is 0~1;

• Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided;

• Adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count =1.5×10?/L; Platelet count =100×10?/L; Hemoglobin =90 g/L; Alanine aminotransferase = 2.5 ULN; Aspartate aminotransferase =2.5 times ULN; Total bilirubin = 1.5 ULN; Serum creatinine =1.5 ULN with creatinine clearance =60 mL/min [as measured or calculated by Cockcroft and Gault formulas]);

• At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug

• Subjects voluntarily join this study, with good compliance and cooperation in safety and survival follow-up.

Exclusion Criteria:

• Exposure to other antitumor therapies before enrollment;

• Patients who only received segmental resection and wedge resection;

• Patients with any history of active autoimmune disease or autoimmune disease;

• Complicated diseases that require the use of immunosuppressive drugs; concurrent diseases that require the use of immunosuppressive agents for systemic or locally absorbable corticosteroids;

• Combined with severe heart disease, or combined with New York Heart Association (NYHA) grade 3 or 4 cardiac insufficiency;

• Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease;

• Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);

• Have received preventive or attenuated vaccines within 4 weeks before the first administration;

• Patients are unsuitable for participation in this research after comprehensive assessment by the researchers.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC

Intervention

Drug:
• Toripalimab
This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory,to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	3-year DFS rate	DFS is defined as time from randomization to disease recurrence (determined by CT or MRI scan and/or pathologic disease on biopsy) or death (from any cause) by investigator assessment. 3-year DFS rate is Disease-Free Survival at 3 Years.	From date of randomisation up to approximately 5 years
Secondary	DFS	DFS is defined as time from randomization to disease recurrence (determined by CT or MRI scan and/or pathologic disease on biopsy) or death (from any cause) by investigator assessment.	From date of randomisation up to approximately 10 years
Secondary	3-year OS rate	Defined as the percentage of patients alive at 3 years, respectively, estimated from a Kaplan Meier plot of OS at the time of the primary analysis	From date of randomization up to approximately 5 years
Secondary	5-year OS rate	Defined as the percentage of patients alive at 5 years, respectively, estimated from a Kaplan Meier plot of OS at the time of the primary analysis	From date of randomization up to approximately 5 years
Secondary	OS	OS is defined as the time from the date of randomisation until death due to any cause.	From date of randomization up to approximately 10 years
Secondary	Safety and tolerability in overall population	AEs graded by CTCAE version 5.0	From date of randomisation up to approximately 10 years